Charles River Laboratories International, Inc. (CRL) — Analysis Summary
Charles River Laboratories International, Inc. (CRL) has a market cap of $14.15B with year-over-year revenue growth of -0.9%. Net margin stands at -3.6%. The stock trades at a P/E ratio of -59.3.
Key Takeaways
- Revenue changed -0.9% year-over-year
- Net margin of -3.6%
- P/E ratio of -59.3
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, CRL posted revenue growth of -0.9% and trades at a P/E of -59.3.
Charles River Laboratories International, Inc. (CRL)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.8x — highly leveraged, potential refinancing risk
Interest coverage at 0.8x — earnings do not cover interest payments
Operating margin (2.3%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Net income fell 65.2% vs the prior period.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
19,700
Headquarters
WILMINGTON, MA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.